| Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. | |
| | |
MedLine Citation:
|
PMID: 8042615 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Seven patients in second complete remission of acute myeloid leukemia (AML) aged 19-65 years were treated with polyethylene glycolated interleukin-2 (PEG IL-2), 1 x 10(6) U/M2 IV weekly as the sole postremission therapy. Second remission duration was in the range of 4-49+ months, and three patients had a second remission duration substantially longer than their first (6, 21+, and 42+ months). The results suggest that PEG IL-2 may prolong second remission duration in AML and that a prospective randomized study designed to test that idea is warranted. |
| | |
Authors:
|
P H Wiernik; J P Dutcher; M Todd; G Caliendo; L Benson |
Related Documents
:
|
16518605 - Optimal treatment intensity in children with down syndrome and myeloid leukaemia: data ... 18784805 - Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. 20938465 - Association of abcb1 polymorphisms with survival and in vitro cytotoxicty in de novo ac... 15975045 - Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial... 384435 - Attempts to increase the surviving length in skin flaps by a moist environment. 21982065 - Improving the clinical risk score: an analysis of molecular biomarkers in the era of mo... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: American journal of hematology Volume: 47 ISSN: 0361-8609 ISO Abbreviation: Am. J. Hematol. Publication Date: 1994 Sep |
Date Detail:
|
Created Date: 1994-08-19 Completed Date: 1994-08-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7610369 Medline TA: Am J Hematol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 41-4 Citation Subset: IM |
Affiliation:
|
Albert Einstein Cancer Center/Department of Oncology, Montefiore Medical Center, Bronx, New York 10467-2490. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Humans Interleukin-2 / analogs & derivatives*, therapeutic use, toxicity Leukemia, Myeloid, Acute / drug therapy* Male Middle Aged Polyethylene Glycols |
| Chemical | |
Reg. No./Substance:
|
0/Interleukin-2; 0/Polyethylene Glycols; 0/interleukin-2, polyethylene glycol-modified |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patien...
Next Document: Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-tra...